½ÃÀ庸°í¼­
»óǰÄÚµå
1392035

³úÇϼöü ¾Ï ½ÃÀå : ¾Ï À¯Çüº°, È£¸£¸ó À¯Çüº°, Ä¡·á À¯Çüº°, ¿¬·ÉÃþº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°

Pituitary Cancer Market, By Cancer Type, By Hormone Type, By Treatment Type, By Age Group, By End User, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ³úÇϼöü ¾Ï ½ÃÀå ±Ô¸ð´Â 2023³â 3¾ï 8,070¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â 7¾ï 2,330¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ¿¹Ãø ±â°£(2023³â-2030³â)¿¡ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.6%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 3¾ï 8,070¸¸ ´Þ·¯
¾÷Àû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023³â-2030³â
¿¹Ãø ±â°£ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.60% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 7¾ï 2,330¸¸ ´Þ·¯
±×¸² 1. ¼¼°è ³úÇϼöü ¾Ï ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Pituitary Cancer Market-IMG1

³úÇϼöü ¾ÏÀÇ ¿øÀÎÀº Àß ¾Ë·ÁÁ® ÀÖÁö ¾Ê½À´Ï´Ù. ±×·¯³ª À¯ÀüÇаú È£¸£¸ó ºÒ±ÕÇüÀÌ ¿øÀÎ ÀÏ ¼ö ÀÖ½À´Ï´Ù. ³úÇϼöü ¾ÏÀÇ ´ëºÎºÐÀº ¼±Á¾, Áï ºñ¾Ï¼ºÀÔ´Ï´Ù. ³úÇϼöü ¾ÏÀº ¾ç¼º(ºñ¾Ï¼º)ÀÎ ³úÇϼöü ³¶Á¾¸¸Å­ ÈçÇÏÁö ¾Ê½À´Ï´Ù.

³úÇϼöü ¾ÏÀÇ Áõ»óÀº Á¾Á¾ µÎÅë, ½Ã·Â º¯È­, üÁß °¨¼Ò ¶Ç´Â üÁß Áõ°¡ ºÒ´É, ±â¾ï·Â°ú ÁýÁß·ÂÀÇ ÀúÇÏ µîÀÌ ÀÖ½À´Ï´Ù. ³úÇϼöü ¾ÏÀÇ À¯Çü¿¡ µû¶ó È£¸£¸óÀÌ °úµµÇÏ°Ô ºÐºñµÇ¾î Äí½Ì ÁõÈıºÀ̶ó´Â Áúº´À¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÁúȯÀ¸·Î ÀÎÇØ ÇÁ·Î¶ôƾÀÌ °úµµÇÏ°Ô ºÐºñµÇ¾î °¡½¿°ú ÆÈÀÇ ÇǺΰ¡ ¾ã¾ÆÁö°Å³ª ¹ß Ç㸮ÀÇ »À°¡ ¾àÇØÁö´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ½ÅÇÏÁö ¾ÊÀºµ¥ À¯¹æ¿¡¼­ ¿ìÀ¯°¡ ºÐºñµÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ó±¼ÀÌ ºÓ¾îÁö°Å³ª ÆÈ°ú ´Ù¸®ÀÇ Ç÷¾ÐÀÌ ³ô¾ÆÁö´Â µî Ç÷¾Ð¿¡ ´Ù¾çÇÑ º¯È­¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

³úÇϼöü ¾ÏÀÇ ¹ß»ý °Ç¼ö Áõ°¡, ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Ä¡·á¹ýÀÇ ±â¼úÀû Áøº¸°¡ ¿¹Ãø ±â°£ Áß ¼¼°è ³úÇϼöü¾Ï ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ±¹¹ÎÀÇ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ºñħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ³úÇϼöü ¾ÏÀÇ Àü¹® ¼­ºñ½º¸¦ Á¦°øÇÏ´Â º´¿ø ¹× Ŭ¸®´Ð ¼ö Áõ°¡µµ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ¾Ï Ä¡·á¿¡ µå´Â ºñ¿ëÀÇ ³ôÀÌ´Â ¿¹Ãø ±â°£¿¡ °ÉÃÄ ¼¼°è ³úÇϼöü ¾Ï ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿äÀÎÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­´Â ¼¼°è ³úÇϼöü ¾Ï ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023³â-2030³â) ½ÃÀå ±Ô¸ð¿Í º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã¿Í ½ÂÀÎ, ½ÃÀ嵿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀïÀü·« µî¿¡ °üÇÑ ÁÖ¿ä °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ¹ÙÅÁÀ¸·Î ¼¼°è ³úÇϼöü ¾Ï ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ³úÇϼöü ¾Ï ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, ÆÇ¸ÅÀÚ, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µîÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ³úÇϼöü¾Ï ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • ¹ß»ý·ü°ú À¯º´·ü Áõ°¡
  • ÀÇ·á ¿µ»ó ó¸® ¹× Áø´ÜÀÇ Áøº¸
  • ¿¬±¸°³¹ß Áõ°¡
  • ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
  • ÀνÄÀÌ ÇÑÁ¤ÀûÀ̰í Áø´ÜÀÌ Áö¿¬µÈ´Ù
  • Ç¥ÁØÈ­µÈ Ä¡·á ÁöħÀÇ ºÎÁ·
  • ÁøÇ༺ ³úÇϼöü ¾Ï¿¡ ´ëÇÑ Á¦ÇÑµÈ Ä¡·á ¿É¼Ç
  • ÀǾàǰ °³¹ßÀÇ °úÁ¦
    • ±âȸ
  • Ç¥Àû ¿ä¹ýÀÇ °³¹ß
  • º´¿ë ¿ä¹ý
  • ¼ö¼ú ±â¼úÀÇ Áøº¸
  • »õ·Î¿î À̹ÌÁö ¸ð´Þ¸®Æ¼ °³¹ß
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå ³úÇϼöü ¾Ï ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ³úÇϼöü ¾Ï ½ÃÀå : ¾Ï À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ³úÇϼöü ¼±Á¾(¾ç¼º Á¾¾ç)
  • ³úÇϼöü¾Ï(¾Ç¼ºÁ¾¾ç)

Á¦6Àå ³úÇϼöü¾Ï ½ÃÀå : È£¸£¸ó À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ÇÁ·Î¶ôƼ³ë¸¶
  • ¼ºÀå È£¸£¸ó ºÐºñ Á¾¾ç(÷´Ü °Å´ëÁõ)
  • ºÎ½ÅÇÇÁúÀÚ±ØÈ£¸£¸ó ºÐºñÁ¾¾ç(Äí½Ìº´)
  • °©»ó¼± ÀÚ±Ø È£¸£¸ó ºÐºñ Á¾¾ç(TSHoma)
  • gonadotropin ºÐºñ Á¾¾ç

Á¦7Àå ³úÇϼöü ¾Ï ½ÃÀå : Ä¡·á À¯Çüº°(2018³â-2030³â)

  • ¼Ò°³
  • ¼ö¼ú
  • ¹æ»ç¼±Ä¡·á
  • ¾à¹° ¿ä¹ý(¿¹: µµÆÄ¹Î ÀÛ¿ëÁ¦, ¼Ò¸¶Å佺Ÿƾ À¯»çü, È£¸£¸ó º¸Ãæ ¿ä¹ý)
  • Ç¥Àû¿ä¹ý
  • È­Çпä¹ý

Á¦8Àå ³úÇϼöü¾Ï ½ÃÀå : ¿¬·ÉÃþº°(2018³â-2030³â)

  • ¼Ò°³
  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦9Àå ³úÇϼöü¾Ï ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2018³â-2030³â)

  • ¼Ò°³
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • ¾Ï Ä¡·á ¼¾ÅÍ
  • ¿¬±¸±â°ü

Á¦10Àå ³úÇϼöü¾Ï ½ÃÀå : Áö¿ªº°(2018³â-2030³â)

  • ¼Ò°³
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN ±¹°¡
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï ±¸µµ

  • Novartis International AG
  • Pfizer Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Endocyte
  • RECORDATI GROUP
  • Camurus AB
  • Endeavor Biomedicines, Inc
  • Debiopharm International SA

Á¦12Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
BJH 23.12.21

The global pituitary cancer market size was estimated to be US$ 380.7 million in 2023 and is projected to reach US$ 723.2 million by 2030, growing at a CAGR of 9.6% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 380.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 9.60% 2030 Value Projection: US$ 723.3 Mn
Figure 1. Global Pituitary Cancer Market Share (%), By Region, 2023
Pituitary Cancer Market - IMG1

The cause of pituitary cancer is not well understood. But genetics and hormonal imbalances may play a role. Most pituitary tumors are adenomas, or noncancerous. They are not as common as pituitary gland cysts, which are benign (noncancerous).

Symptoms of pituitary cancer often include headaches, vision changes, loss of weight or an inability to gain weight, and trouble with memory and concentration. Some types of pituitary tumors release too many hormones, which can lead to a disease called Cushing's syndrome. In some cases, this disease causes the body to produce too much prolactin, which can cause thinning of the skin in the chest and arms, and weak bones in the legs and feet. Other forms of this condition can cause the breasts to make milk, even when the person is not pregnant. The condition can also cause a wide range of changes in blood pressure, including a flushed face and high blood pressure in the arms or legs.

Market Dynamics:

Rising incidences of pituitary tumors, increasing investments in research and development activities, and technological advancements in treatment methods are expected to drive growth of the global pituitary cancer market during the forecast period. In addition, increased awareness among the populace has led to a higher demand for noninvasive treatments. The market is also driven by a rise in the number of hospitals and clinics that offer specialized services for pituitary tumors.

However, the high cost of cancer treatments is a major factor expected to impede the growth of the global pituitary cancer market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global pituitary cancer market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pituitary cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global pituitary cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pituitary cancer market

Global Pituitary Cancer Market Detailed Segmentation:

  • By Cancer Type:
    • Pituitary Adenoma (Benign Tumor)
    • Pituitary Carcinoma (Malignant Tumor)
  • By Hormone Type:
    • Prolactinoma
    • Growth Hormone-Secreting Tumor (Acromegaly)
    • Adrenocorticotropic Hormone-Secreting Tumor (Cushing's Disease)
    • Thyroid-Stimulating Hormone-Secreting Tumor (TSHoma)
    • Gonadotropin-Secreting Tumor
  • By Treatment Type:
    • Surgery
    • Radiation Therapy
    • Medications (e.g., dopamine agonists, somatostatin analogs, hormone replacement therapy)
    • Targeted Therapy
    • Chemotherapy
  • By Age Group:
    • Pediatric
    • Adult
  • By End User:
    • Hospitals
    • Specialty Clinics
    • Cancer Treatment Centers
    • Research Institutes
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Company Profile:
    • Novartis International AG
    • Pfizer Inc.
    • Ipsen Biopharmaceuticals, Inc.
    • Endocyte
    • RECORDATI GROUP
    • Camurus AB
    • Endeavor Biomedicines, Inc.
    • Debiopharm International SA

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Pituitary Cancer, By Cancer Type
    • Market Pituitary Cancer, By Hormone Type
    • Market Pituitary Cancer, By Treatment Type
    • Market Pituitary Cancer, By Age Group
    • Market Pituitary Cancer, By End User
    • Market Pituitary Cancer, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing Incidence and Prevalence
  • Advancements in Medical Imaging and Diagnostics
  • Increased Research and Development
  • Growing Demand for Personalized Medicine
    • Restraints
  • Limited Awareness and Delayed Diagnosis
  • Lack of Standardized Treatment Guidelines
  • Limited Treatment Options for Aggressive Pituitary Cancers
  • Challenges in Drug Development
    • Opportunities
  • Development of Targeted Therapies
  • Combination Therapies
  • Advancements in Surgical Techniques
  • Development of Novel Imaging Modalities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Pituitary Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Pituitary Cancer Market , By Cancer Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Pituitary Adenoma (Benign Tumor)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)
  • Pituitary Carcinoma (Malignant Tumor)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Mn)

6. Pituitary Cancer Market , By Hormone Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Prolactinoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Growth Hormone-Secreting Tumor (Acromegaly)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Adrenocorticotropic Hormone-Secreting Tumor (Cushing's Disease)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Thyroid-Stimulating Hormone-Secreting Tumor (TSHoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Gonadotropin-Secreting Tumor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

7. Pituitary Cancer Market , By Treatment Type, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018- 2030
    • Segment Trends
  • Surgery
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Radiation Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Medications(e.g., dopamine agonists, somatostatin analogs, hormone replacement therapy)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

8. Pituitary Cancer Market , By Age Group, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

9. Pituitary Cancer Market , By End User, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Cancer Treatment Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)
  • Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Million)

10. Pituitary Cancer Market , By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Country 2018-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Hormone Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Hormone Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Hormone Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Hormone Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Hormone Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030,(US$ Mn)
  • GCC
  • Israel
  • North Africa
  • Central Africa
  • Rest of Middle East & Africa

11. Competitive Landscape

  • Novartis International AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Ipsen Biopharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Endocyte
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • RECORDATI GROUP
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Camurus AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Endeavor Biomedicines, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Debiopharm International SA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

12. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦